Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial Post author:admin Post published:March 12, 2025 Post category:uncategorized NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. You Might Also Like Chicken Caesar Salad October 20, 2023 New imaging method reveals nanodomains inside ALS-linked protein droplets November 26, 2025 Immediate skin-to-skin contact offers significant health advantages for infants October 22, 2025